Recent News for the Wellstat Group of CompaniesMay 22, 2012, Wellstat Grants BTG European Distribution Rights to Investigational Antidote for 5-FU Overexposure
July 6, 2011, Wellstat Grants U.S. Distribution Rights to its Investigational Antidote for 5-FU Overexposure to Specialist Healthcare Company BTG
May 20, 2010, Wellstat Investigational Drug Shows Life-Saving Potential in Treating Toxicity of Widely Used Cancer Chemotherapy
October 21, 2009, Wellstat Therapeutics and Sanofi_aventis Enter Agreement on PN2034, Novel Therapy for Type II Diabetes
October 21, 2009, Sanofi_aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes
May 14, 2009, Wellstat Therapeutics Corporation: Investigational Drug Shows Promise as Treatment for Overexposure to Common Cancer Chemotherapy
|
